In 2018,European Journal of Medicinal Chemistry included an article by Pan, Liangkun; Zheng, Qiang; Chen, Yu; Yang, Rui; Yang, Yanyan; Li, Zhongjun; Meng, Xiangbao. Safety of Methyl 3-(bromomethyl)benzoate. The article was titled 《Design, synthesis and biological evaluation of novel naphthoquinone derivatives as IDO1 inhibitors》. The information in the text is summarized as follows:
Indoleamine 2,3-dioxygenase 1 mediated kynurenine pathway of tryptophan degradation is identified as an appealing and novel target in immunotherapy for the treatment of cancer. In this study, a novel series of naphthoquinone derivatives were synthesized, characterized and evaluated for their inhibitory activities against IDO1, and their structure-activity relationship was investigated. Among them, five compounds, e.g., I,displayed potent IDO1 inhibitory activities with IC50 values ranging between 18 and 61 nM, which are more potent than INCB024360 undergoing clin. trial III evaluation. In addition, three compounds, e.g. II, decreased the kynurenine levels in rat plasma by 30%-50%. Compounds exhibiting excellent IDO1 inhibitory activities were also evaluated for their inhibitory activities against tryptophan 2,3-dioxygenase (TDO). Of which, compound II (IDO1 IC50 = 120 nM) showed promising TDO inhibition (IC50 72 nM) and was identified as an IDO1/TDO dual inhibitor. In addition to this study using Methyl 3-(bromomethyl)benzoate, there are many other studies that have used Methyl 3-(bromomethyl)benzoate(cas: 1129-28-8Safety of Methyl 3-(bromomethyl)benzoate) was used in this study.
Methyl 3-(bromomethyl)benzoate(cas: 1129-28-8) belongs to organobromine compounds. A variety of minor organobromine compounds are found in nature, but none are biosynthesized or required by mammals.Safety of Methyl 3-(bromomethyl)benzoate Organobromine compounds have fallen under increased scrutiny for their environmental impact.
Referemce:
Bromide – Wikipedia,
bromide – Wiktionary